Summary
This prediction ended on 05.03.22 with a price of €18.22. The BUY prediction by Gerardix finished with a performance of 26.39%. A total of €1.29 was paid as dividends for this prediction. Gerardix has 70% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| GSK plc | 4.987% | 4.987% | 22.026% | 29.055% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to Gerardix what are the pros and cons of GSK plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Very high dividend yield expected
Fair valuation
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Innovative
Differentiated customer and product portfolio
Cons
Comments by Gerardix for this prediction
In the thread GlaxoSmithKline plc diskutieren
In the thread Trading GlaxoSmithKline plc
Die von Gerardix gewählte maximale Laufzeit wurde überschritten